Last reviewed · How we verify
NCT07346521: G-SCOGE
Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy
trial in HELICOBACTER PYLORI INFECTIONS in 1,000 participants. Currently enrolling.
16 December 2026
Quick facts
| Lead sponsor | Sigmund Freud PrivatUniversitat |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 16 December 2025 |
| Primary completion | 16 December 2026 |
| Estimated completion | 16 December 2026 |
| Sites | 1 location across Austria |
Conditions studied
- HELICOBACTER PYLORI INFECTIONS — all drugs for HELICOBACTER PYLORI INFECTIONS →
- Intestinal Metaplasia — all drugs for Intestinal Metaplasia →
- Barett's Esophagus — all drugs for Barett's Esophagus →
Sponsor
Sigmund Freud PrivatUniversitat
Who can join
30 and older, any sex, with HELICOBACTER PYLORI INFECTIONS or Intestinal Metaplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy. Endoscopic screening of the stomach is yet not acceptet as a standard screening procedure in Western countries. However, Helicobacter pylori infection is known to increase the risk of developing gastric cancer. This study will look at the prevalence of Helicobacter pylori infection in asymptomatic patients who have an additional gastroscopy during the same session as their screening colonoscopy. It will also record other early tissue changes or risk factors for stomach cancer, such as intestinal metaplasia and Barrett's mucosa. The main questions this study aims to answer are: * How often is Helicobacter pylori found in adults without upper gastrointestinal symptoms by use of OGD? * Are there any correlations between H. pylori infection and other risk factors, such as BMI, smoking, alcohol consumption, or a family history of colorectal and/or stomach cancer? About 1000 participants are expected to take part. Adults undergoing a screening colonoscopy at a private endoscopy center will be offered the chance to have an additional gastroscopy if they meet the study's inclusion criteria (no previous Helicobacter pylori infection and no upper gastrointestinal symptoms). Small tissue samples (biopsies) will be taken from the stomach and lower esophagus during the gastroscopy. Biopsies will be checked histologically for the presence of Helicobacter pylori and early tissue changes. During the gastroscopy, no additional procedures or biopsies will be done beyond what is normally performed during a routine examination. Everything done during this procedure follows the standard steps of a regular gastroscopy. All data will be coded to protect participant privacy. Researchers will use statistical methods to find out how common Helicobacter pylori infection is and whether it is related to other lifestyle or family risk factors or tissue changes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07346521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HELICOBACTER PYLORI INFECTIONS
Currently open trials in the same condition.
- NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting
- NCT07335406 — Registry for the Management of Helicobacter Pylori Infection in Shandong Province · recruiting
- NCT07246681 — Lignin in Treatment of Helicobacter Pylori Infection · Phase 3 · active not recruiting
- NCT07179159 — Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication · NA · recruiting
- NCT07306988 — Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. · Phase 4 · recruiting
Other Sigmund Freud PrivatUniversitat trials
Trials by the same sponsor.
- NCT07231198 — Detection of Microplastics in Patients With Periodontitis · not yet recruiting
- NCT07299981 — Quantitative Net Water Uptake as a Predictor of Functional Outcomes After Intravenous Thrombolysis in Acute Ischemic Str · not yet recruiting
- NCT07299994 — Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease · not yet recruiting
- NCT06803706 — Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community · NA · recruiting
- NCT06688877 — The Study is About the influence of the Combination of Music and Noise Cancelling as a Non-pharmacological Aid in Reducin · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07346521 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sigmund Freud PrivatUniversitat
- Last refreshed: 9 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07346521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing